AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15981065 — intervention group
Group type: COMPARATOR
Intervention: Normal meal preoperatively (normal meal preoperatively group)
Number of subjects: 250
Study 12521651 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous group (168 days without a pill-free interval)
Number of subjects: 32
Study 12521651 — intervention group
Group type: COMPARATOR
Intervention: Standard group (6 cycles of 28 days)
Number of subjects: 32
Study 12521651 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous group
Number of subjects: 32
Study 12521651 — intervention group
Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 32
Study 9661567 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (2 micrograms/kg)
Number of subjects: 30
Study 9661567 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (70 micrograms/kg)
Number of subjects: 30
Study 9661567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7634942 — intervention group
Group type: EXPERIMENTAL
Intervention: Extramucosal pyloroplasty
Number of subjects: 107
Study 7634942 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pyloroplasty)
Number of subjects: 107
Study 2694742 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (single preoperative dose)
Number of subjects: 166
Study 2694742 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 166
Study 786668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular meperidine (100 mg)
Number of subjects: 0
Study 786668 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral meperidine (150 mg)
Number of subjects: 0
Study 786668 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of intramuscular dose (mg/kg)
Number of subjects: 0
Study 31613994 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearsonic ultrasonic tip
Number of subjects: 20
Study 31613994 — intervention group
Group type: COMPARATOR
Intervention: Reciproc R40 instrument
Number of subjects: 20
Study 29779350 — intervention group
Group type: EXPERIMENTAL
Intervention: pd‐FⅨ (plasma derived coagulation Factor Ⅸ concentrate)
Number of subjects: 36
Study 28579415 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix alone (100 mg BID, 200 mg BID, 300 mg BID, 400 mg QD, 600 mg QD)
Number of subjects: 271
Study 28579415 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix with add-back therapy (200 mg BID plus continuous low-dose E2 0.5 mg/norethindrone acetate 0.1 mg or elagolix 300 mg BID plus E2 1 mg continuously and cyclical P 200 mg)
Number of subjects: 271
Study 28579415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 28579415 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse events (AEs)
Number of subjects: 271
Study 25707611 — intervention group
Group type: EXPERIMENTAL
Intervention: Blosozumab 270 mg every 2 weeks (Q2W)
Number of subjects: 120
Study 25707611 — intervention group
Group type: EXPERIMENTAL
Intervention: Blosozumab 180 mg every 2 weeks (Q2W)
Number of subjects: 120
Study 25707611 — intervention group
Group type: COMPARATOR
Intervention: Blosozumab
Number of subjects: 120
Study 23820652 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic nerve blockade in addition to intrarectal lidocaine gel
Number of subjects: 473
Study 23820652 — intervention group
Group type: COMPARATOR
Intervention: Intrarectal lidocaine gel
Number of subjects: 473
Study 21131286 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider training and materials to improve risk factor reporting
Number of subjects: 0
Study 21131286 — intervention group
Group type: COMPARATOR
Intervention: Control facilities (no intervention)
Number of subjects: 0
Study 21131286 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-post difference for intervention
Number of subjects: 0
Study 21131286 — intervention group
Group type: COMPARATOR
Intervention: Pre-post difference for control
Number of subjects: 0
Study 21131286 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS cases from intervention
Number of subjects: 0
Study 21131286 — intervention group
Group type: COMPARATOR
Intervention: AIDS cases from control
Number of subjects: 0
Study 19032723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast 30 mg single administration followed by 30 mg b.i.d. for 14 days
Number of subjects: 18
Study 19032723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16452912 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg daily)
Number of subjects: 400
Study 16452912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 14604716 — intervention group
Group type: EXPERIMENTAL
Intervention: Applanation ultrasound (US)
Number of subjects: 377
Study 14604716 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced operators
Number of subjects: 377
Study 11281167 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid emulsion (1.6 ml)
Number of subjects: 45
Study 11281167 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid emulsion (3.2 ml)
Number of subjects: 45
Study 11281167 — intervention group
Group type: COMPARATOR
Intervention: Control emulsion (0 ml oleic acid)
Number of subjects: 45
Study 11281167 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid treatment
Number of subjects: 45
Study 9012637 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VII coagulant activity (VIIc)
Number of subjects: 1514
Study 9012637 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in VIIc
Number of subjects: 1514
Study 9012637 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VII antigen (VIIag)
Number of subjects: 1514
Study 9012637 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial correlation coefficients after adjustment for sex and race
Number of subjects: 1514
Study 8140906 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (daily dose 20-60 mg)
Number of subjects: 22
Study 8140906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8140906 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 22
Study 2849539 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 treatment (2.9 mmol of NaHCO3.kg‐1 body weight)
Number of subjects: 10
Study 2849539 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (17 mmol of NaCl)
Number of subjects: 10
Study 2849539 — intervention group
Group type: COMPARATOR
Intervention: No-drink treatment
Number of subjects: 10
Study 2062514 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsimultaneous stereoscopic fluorescein angiography
Number of subjects: 0
Study 560645 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tyramine
Number of subjects: 80
Study 560645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31580100 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental training condition (discriminating between faces that differed in feature size or spacing across 10 levels of difficulty)
Number of subjects: 81
Study 31580100 — intervention group
Group type: COMPARATOR
Intervention: Active control training condition (playing the standard version of Guess Who)
Number of subjects: 81
Study 30178577 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral aspirin
Number of subjects: 60
Study 30178577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27846743 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor, 5 mg od)
Number of subjects: 30
Study 27846743 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (AT1R antagonist, 8 mg od)
Number of subjects: 30
Study 27846743 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 30
Study 24520880 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m) Tc‐DTPA aerosol scintigraphy in nonsmoking COPD patients
Number of subjects: 84
Study 24520880 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 84
Study 27366374 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 0
Study 27366374 — intervention group
Group type: COMPARATOR
Intervention: Control (standard technique)
Number of subjects: 0
Study 20884019 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 47
Study 20884019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 20884019 — intervention group
Group type: EXPERIMENTAL
Intervention: LVAD implantation
Number of subjects: 47
Study 19365150 — intervention group
Group type: EXPERIMENTAL
Intervention: ABIO-08/01 (10 mg)
Number of subjects: 16
Study 19365150 — intervention group
Group type: EXPERIMENTAL
Intervention: ABIO-08/01 (20 mg)
Number of subjects: 16
Study 19365150 — intervention group
Group type: EXPERIMENTAL
Intervention: ABIO-08/01 (40 mg)
Number of subjects: 16
Study 19365150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17498886 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin and flutamide for 2 months before and during radiation therapy (RT) +/− 24 months of goserelin (long-term androgen deprivation plus radiation [LTAD-RT])
Number of subjects: 197
Study 17498886 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin and flutamide for 2 months before and during RT +/− 24 months of goserelin (LTAD-RT)
Number of subjects: 197
Study 15161117 — intervention group
Group type: EXPERIMENTAL
Intervention: lumiracoxib 400 mg once daily
Number of subjects: 183
Study 15161117 — intervention group
Group type: EXPERIMENTAL
Intervention: rofecoxib 50 mg once daily
Number of subjects: 183
Study 15161117 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen 500 mg twice daily
Number of subjects: 183
Study 15161117 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 183
Study 11261891 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 0
Study 11261891 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose chemotherapy
Number of subjects: 0
Study 9540364 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 20
Study 9540364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7905523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with N-butyl-deoxynojirimycin (SC-48334) and zidovudine (1000 mg every 8 h and 100 mg every 8 h, respectively)
Number of subjects: 118
Study 7905523 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine and placebo
Number of subjects: 118
Study 7905523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with N-butyl-deoxynojirimycin (SC-48334) and zidovudine
Number of subjects: 118
Study 2594133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular injection of morphine
Number of subjects: 50
Study 2594133 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of morphine
Number of subjects: 50
Study 31670776 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transversus abdominis plane block
Number of subjects: 90
Study 31670776 — intervention group
Group type: COMPARATOR
Intervention: Sham block (subcutaneous)
Number of subjects: 90
Study 30951210 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving at least a 1-level reduction in WHO risk drinking levels by the end of treatment
Number of subjects: 1226
Study 30951210 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving at least a 2-level reduction in WHO risk drinking levels by the end of treatment
Number of subjects: 1226
Study 30951210 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO risk level reductions
Number of subjects: 1226
Study 29279933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (1000 mg intravenous preoperative dose)
Number of subjects: 500
Study 29279933 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% sodium chloride intravenous preoperative dose)
Number of subjects: 500
Study 29279933 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin vs Saline
Number of subjects: 500
Study 25925742 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold standard programme for alcohol cessation intervention, including structured patient education, weekly intervention meetings, thiamine and B-vitamins, alcohol withdrawal prophylaxis, and disulfiram for abstinence support.
Number of subjects: 0
Study 25925742 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 24393553 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg linagliptin once daily
Number of subjects: 36
Study 24393553 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg linagliptin
Number of subjects: 36
Study 20680276 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (closed reduction followed by fragment excision)
Number of subjects: 16
Study 20680276 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (closed reduction)
Number of subjects: 16
Study 19690484 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-cm side limb
Number of subjects: 44
Study 19690484 — intervention group
Group type: COMPARATOR
Intervention: 6-cm side limb
Number of subjects: 44
Study 16374142 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day after 12 months
Number of subjects: 36
Study 16374142 — intervention group
Group type: COMPARATOR
Intervention: Lipid-lowering diet (control period)
Number of subjects: 36
Study 15185228 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete resection (CR)
Number of subjects: 539
Study 15185228 — intervention group
Group type: COMPARATOR
Intervention: Less than complete resection (MR or PR)
Number of subjects: 539
Study 15185228 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residual (MR)
Number of subjects: 539
Study 15185228 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial resection (PR)
Number of subjects: 539
Study 10874282 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 30
Study 10874282 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 30
Study 9184014 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban sample (Madrid)
Number of subjects: 1259
Study 9184014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural sample (Arévalo, Avila)
Number of subjects: 1259
Study 1410747 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 3‐5 micrograms/kg, 5 minutes before implantation of craniostate
Number of subjects: 34
Study 1410747 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous infiltration of mepivacaine 2% at craniostate fixation points
Number of subjects: 34
Study 1410747 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockade of frontal and occipital nerves
Number of subjects: 34
Study 2866291 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion (2 litres of 0.9% saline over 1 hour)
Number of subjects: 0
Study 2866291 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet (10 mmol/day)
Number of subjects: 0
Study 2866291 — intervention group
Group type: COMPARATOR
Intervention: Normal sodium intake (150 mmol/day)
Number of subjects: 0
Study 2866291 — intervention group
Group type: COMPARATOR
Intervention: High salt intake (350 mmol/day)
Number of subjects: 0
Study 30893216 — intervention group
Group type: EXPERIMENTAL
Intervention: Short InterTAN device (180‐200 mm)
Number of subjects: 108
Study 30893216 — intervention group
Group type: COMPARATOR
Intervention: Long InterTAN device (260‐460 mm)
Number of subjects: 108
Study 29172800 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire (Group A)
Number of subjects: 842
Study 29172800 — intervention group
Group type: COMPARATOR
Intervention: GP-administered questionnaire (Group B)
Number of subjects: 842
Study 29172800 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 842
Study 28304291 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Resistance (top HOMA-IR quartile)
Number of subjects: 489
Study 25899029 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion (0.15 mmol/kg body weight/h)
Number of subjects: 342
Study 25899029 — intervention group
Group type: COMPARATOR
Intervention: Control (no sodium bicarbonate infusion)
Number of subjects: 342
Study 23743672 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine group (SG); n=54
Number of subjects: 100
Study 23743672 — intervention group
Group type: COMPARATOR
Intervention: Turning group (TG); n=46
Number of subjects: 100
Study 20184225 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal oral solution (600 mg)
Number of subjects: 24
Study 20184225 — intervention group
Group type: COMPARATOR
Intervention: Triflusal capsules (300 mg x 2)
Number of subjects: 24
Study 19133017 — intervention group
Group type: EXPERIMENTAL
Intervention: HD with PES
Number of subjects: 8
Study 19133017 — intervention group
Group type: COMPARATOR
Intervention: HDF with POX
Number of subjects: 8
Study 19133017 — intervention group
Group type: COMPARATOR
Intervention: HDF with PSU
Number of subjects: 8
Study 19133017 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 8
Study 15893540 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat (5 mg)
Number of subjects: 12
Study 15893540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12849799 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive patch (group 1 and group 2)
Number of subjects: 124
Study 12849799 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives (OCs)
Number of subjects: 124
Study 10593469 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral infraclavicular approach (n=20)
Number of subjects: 40
Study 10593469 — intervention group
Group type: COMPARATOR
Intervention: Axillary approach (n=20)
Number of subjects: 40
Study 8941827 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelon‐Silver
Number of subjects: 2
Study 8941827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac‐Silver
Number of subjects: 2
Study 8941827 — intervention group
Group type: COMPARATOR
Intervention: Dispersalloy
Number of subjects: 2
Study 8941827 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Chelon‐Silver, Ketac‐Silver, Dispersalloy)
Number of subjects: 2
Study 1768561 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (125 mg, three oral doses at 2-hour intervals)
Number of subjects: 8
Study 1768561 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two doses)
Number of subjects: 8
Study 1768561 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of soluble paracetamol with levodopa
Number of subjects: 8
Study 1768561 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of radiolabelled DTPA with levodopa
Number of subjects: 8
Study 6456699 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied clindamycin hydrochloride and clindamycin phosphate (2% concentration)
Number of subjects: 0
Study 6456699 — intervention group
Group type: COMPARATOR
Intervention: Hydroalcoholic products (control)
Number of subjects: 0
Study 30376364 — intervention group
Group type: EXPERIMENTAL
Intervention: Kawashima Brain Training (KBT)
Number of subjects: 36
Study 30376364 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Mario Bros (SMB)
Number of subjects: 36
Study 30376364 — intervention group
Group type: COMPARATOR
Intervention: No-training no-contact control group
Number of subjects: 36
Study 28675824 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-shaped swaddling clothing (n=27)
Number of subjects: 39
Study 28675824 — intervention group
Group type: COMPARATOR
Intervention: Conventional swaddling (n=12)
Number of subjects: 39
Study 25455721 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 units oral vitamin D3 every 2 months for 6 months
Number of subjects: 50
Study 25455721 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 50
Study 22773397 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefazolin systemically 10 minutes before tourniquet inflation
Number of subjects: 22
Study 22773397 — intervention group
Group type: COMPARATOR
Intervention: 1 g cefazolin intraosseously in 200 mL of normal saline after tourniquet inflation
Number of subjects: 22
Study 22093786 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus THP & CTX
Number of subjects: 97
Study 22093786 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus THP & CTX
Number of subjects: 97
Study 19418497 — intervention group
Group type: EXPERIMENTAL
Intervention: EPCA‐2.19 assay
Number of subjects: 328
Study 16581485 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE patients
Number of subjects: 40
Study 16581485 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE patients with PH
Number of subjects: 40
Study 12875066 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-epilepsy capsules
Number of subjects: 1090
Study 12875066 — intervention group
Group type: COMPARATOR
Intervention: Luminal (control)
Number of subjects: 1090
Study 10868558 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine syrup (5 mg, 1 mg/mL)
Number of subjects: 121
Study 10868558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 1491863 — intervention group
Group type: EXPERIMENTAL
Intervention: Odorized 35-40% nitrous oxide/oxygen gas mixture
Number of subjects: 0
Study 1491863 — intervention group
Group type: COMPARATOR
Intervention: Odorized placebo gas mixture
Number of subjects: 0
Study 3080865 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (IV)
Number of subjects: 20
Study 3080865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric nutrition (IG)
Number of subjects: 20
Study 29114936 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple training comprising four basic, single‐molecule substances
Number of subjects: 108
Study 29114936 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex training involving four odor mixtures
Number of subjects: 108
Study 29114936 — intervention group
Group type: EXPERIMENTAL
Intervention: Odor‐altering training in which patients changed sets of mixtures every 2 months
Number of subjects: 108
Study 29114936 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall TDI score increase
Number of subjects: 108
Study 27068399 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (300/100 mg)
Number of subjects: 120
Study 27068399 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (800/100 mg)
Number of subjects: 120